Hospitals have started prescribing Koselugo, a treatment for pediatric neurofibromatosis.

AstraZeneca Korea’s Koselugo (ingredient: selumetinib), a neurofibromatosis, has recently passed the Drug Committee (DC) of tertiary hospitals, including Seoul National University Hospital, Samsung Seoul Hospital, Seoul St. Mary's Hospital, Seoul Asan Hospital, and Sinchon Severance Hospital. Some of these hospitals have assigned a prescription code for Koselugo following emergency DC.

Koselugo has been listed for reimbursement starting this year. As a result, it is anticipated that more hospitals will be able to prescribe the drug in the future.

On the third try, Koselugo pa